Hide menu

LiU participation in Chemores, a cancer research program

Eight million SEK is earmarked for a new European research project, Chemores, which will seek to improve the efficacy of chemotherapy for lung cancer and malignant melanoma.

Patients with these forms of cancer often do not respond well to treatment because the cancer cells develop resistance to the cytostatic drugs which normally inhibit or suppress cellular growth and multiplication. Participating scientists will cooperate to identify the causes that trigger such resistance and design drugs that are more effective.

Professor Curt Peterson and his team at the LiU Department of Clinical Pharmacology have been assigned the task of mapping the genetically influenced risk factors that cause some patients to have severe side-effects from medication. Such knowledge would be a step on the way to designing cytostatic drugs and dosage that meet individual needs.

The Chemores project has a five-year work plan and is coordinated by scientists at Karolinska Institutet, KI, in Sweden. Other teams are based in Paris, Madrid, Milan, Munich, Amsterdam and Manchester.


2008-01-22




Page manager: therese.winder@liu.se
Last updated: 2009-06-03